Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99mTc-glucarate for ACS detection in patients with known CAD
NCT00614354Phase 2Completed
- Sponsor
- Molecular Targeting Technologies, Inc.
- Start
- Oct 2008
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of technetium Tc 99m glucarate in acute coronary syndrome (ACS), sponsored by Molecular Targeting Technologies, Inc. Primary endpoint: Image Assessment of 99mTc-glucarate Uptake at 2 hours. Started Oct 2008; status: completed.
02
Drugs
technetium Tc 99m glucarate
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT00614354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00614354.